Evaluation of Patterns of Liver Toxicity in Patients on Antiretroviral and Anti-Tuberculosis Drugs: A Prospective Four Arm Observational Study in Ethiopian Patients
PLoS ONE2014Vol. 9(4), pp. e94271–e94271
Citations Over TimeTop 10% of 2014 papers
Getnet Yimer, Marcus Gry, Wondwossen Amogne, Eyasu Makonnen, Abiy Habtewold, Zelalem Petros, Getachew Aderaye, Ina Schuppe‐Koistinen, Lars Lindquist, Eleni Aklillu
Abstract
HAART associated DILI is mainly cholestatic and mild whereas hepatocellular or mixed pattern with high severity grade is more common in anti-tuberculosis DILI. TB-HIV co-infection, disease severity and concomitant treatment exacerbates the risk of DILI.
Related Papers
- → Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients(2001)832 cited
- → Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results(2005)108 cited
- → Consequences of a Chronic Exposure of Cultured Brain Astrocytes to the Anti-Retroviral Drug Efavirenz and its Primary Metabolite 8-Hydroxy Efavirenz(2016)13 cited
- → Population pharmacokinetics of efavirenz in HIV and TB/HIV coinfected children: the significance of genotype-guided dosing(2019)10 cited
- → Pharmacokinetics of Efavirenz 600mg in Combination with Rifampicin in Chinese HIV/TB Co-Infection Patients(2023)